Epstein-Barr virus (EBV)-specific cytotoxic T lymphocyte (CTL) responses were evaluated in 9 children aged 20-35 months. Autologous EBV-transformed B lymphoblastoid cell lines were used to restimulate EBV-specific memory CTL precursors in vitro. Recognition of individual EBV gene products by bulk CTL lines was evaluated by combining CTL lines with B cell blasts infected with recombinant vaccinia constructs expressing single latent genes. CTL lines from all 9 children recognized one or more EBV latent gene products. All children demonstrated CTL responses against one or more EBV nuclear antigen 3 proteins (EBNA3A, 3B, 3C), and EBNA3C was recognized most frequently. The striking similarity between EBV-specific CTL responses described here in young children and those reported for adults suggests that the EBNA3 family of proteins and latent membrane protein 2A should be considered for inclusion in candidate EBV vaccines.

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/172.3.739DOI Listing

Publication Analysis

Top Keywords

ctl responses
12
ctl lines
12
cytotoxic lymphocyte
8
epstein-barr virus
8
gene products
8
ctl
7
children
5
major histocompatibility
4
histocompatibility complex
4
complex class
4

Similar Publications

Introduction: Toxocarosis in human beings is currently diagnosed by serological assay based on the detection of antibodies against Toxocara antigens. Toxocara canis larvae do not reach the adult stage in paratenic hosts like humans and mice. Therefore experimental infection in mice, which mimics the biology of human infection, might be relevant to get a better understanding of human toxocarosis.

View Article and Find Full Text PDF

Unlabelled: Current influenza vaccination approaches protect against specific viral strains, but do not consistently induce broad and long-lasting protection to the diversity of circulating influenza viruses. Single-cycle viruses delivered to the respiratory tract may offer a promising solution as they safely express a diverse array of viral antigens by undergoing just one round of cell infection in their host and stimulate broadly protective resident memory T-cell responses in the lung. We have previously developed a vaccine candidate called S-FLU, which is limited to a single cycle of infection by inactivation of the hemagglutinin signal sequence and induces a broadly cross-reactive T-cell response and antibodies to neuraminidase, but fails to induce neutralizing antibodies to hemagglutinin after intranasal administration.

View Article and Find Full Text PDF

Purpose: SARS-CoV-2-specific CD8 cytotoxic T lymphocytes (CTLs) are crucial in viral clearance, disease progression, and reinfection control. However, numerous SARS-CoV-2 immunodominant CTL epitopes theoretically are still unidentified due to the genetic polymorphism of human leukocyte antigen class I (HLA-I) molecules.

Methods: The CTL epitopes of SARS-CoV-2 were predicted by the epitope affinity and immunogenicity prediction platforms: the NetMHCpan and the PromPPD.

View Article and Find Full Text PDF

Inhibition of P2X7 receptor mitigates atrial fibrillation susceptibility in isoproterenol-induced rats.

Biochem Biophys Res Commun

January 2025

Department of Cardiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, PR China. Electronic address:

Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that is characterized by atrial electrical remodeling. The P2X7 receptor (P2X7R), an ATP-gated ion channel, has been implicated in cardiovascular pathologies; however, its role in atrial electrical remodeling remains unclear. This study investigated whether inhibition of P2X7R could mitigate isoproterenol (ISO)-induced atrial electrical remodeling in rats and explored the underlying mechanisms.

View Article and Find Full Text PDF

Background: In the past decade, immunotherapy has become a major choice for the treatment of lung cancer, yet its therapeutic efficacy is still relatively limited due to the various immune escape mechanisms of tumors. Based on this, we introduce Neo-BCV, a novel bacterial composite vaccine designed to enhance immune responses against lung cancer.

Methods: We investigated the immune enhancing effect of Neo-BCV through in vivo and in vitro experiments, including flow cytometry, RNA-seq, and Western blot.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!